POET’s $400 Million Lifeline Arrives Amid Fraud Claims and a $500 Million Customer Bet

POET shares jump 43% on $50M Lumilens order but plunge 22% after $400M placement; company faces lawsuit, Marvell order loss, and PFIC relocation.

The week’s trading in POET Technologies encapsulated a company swinging between euphoria and existential dread. Shares rocketed 43% on Thursday after the optical-components specialist announced a strategic supply agreement with Lumilens, only to crash more than 22% the next day when management unveiled a $400 million direct placement that left existing holders facing severe dilution. By Friday’s close the stock had settled at $15.85, having touched an intraday high of $20.30 and a low of $15.00.

The Lumilens deal carries a hefty commercial promise. The initial purchase order for EOI-based engines is valued at $50 million, and the framework agreement could see cumulative orders exceed $500 million over five years. That backlog would go a long way toward justifying the company’s still-lofty valuation — yet the capital raise that funds the production scale-up came at a price that spooked the market.

Investors in the registered direct placement are paying $21 per unit, a significant premium to Friday’s close, with each unit comprising one common share and a warrant exercisable at $26.15 over three years. The proceeds will bankroll manufacturing capacity, potential acquisitions, and expansion of the light-source business. Closing is expected around May 18. After the infusion, POET’s cash balance is estimated at roughly $463 million against an annual burn rate of about $35 million, providing a multi-year runway — assuming no fresh setbacks.

Yet setbacks have already stacked up. A class-action lawsuit accuses POET of securities fraud, alleging it misrepresented the risk of being classified as a Passive Foreign Investment Company and hid adverse tax consequences for U.S. investors. Separately, a POET manager is said to have violated a confidentiality agreement, prompting Marvell Technology’s Celestial-AI unit to cancel all outstanding purchase orders. Analysts have responded accordingly: one trimmed his 2032 price target to $26.50 and slashed the expected annual growth rate to 24%, directly blaming the Marvell loss. The broader analyst consensus, however, stands at just $8.40 — a stark reminder of the skepticism baked into the stock.

The Q1 results underscore the transition phase. Revenue tripled year-on-year to approximately $503,000, while the net loss narrowed to $12.3 million. Selling and administrative costs remained elevated at $12.5 million as the company continues investing heavily in commercial scaling. CFO Thomas Mika is set to retire in 2026, and a successor search is underway.

In an effort to prevent future PFIC issues, POET plans to move its corporate headquarters to the United States. That relocation, combined with the cash cushion from the placement, buys time for the Lumilens deal to deliver. Whether the market grants that patience will depend on how the litigation unfolds — and whether any more Marvell-sized cracks appear in the commercial story.